COMMUNIQUÉS West-GlobeNewswire

Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting
14/02/2024
MENLO PARK, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, [...]
Prime Medicine Announces Proposed Public Offering of Common Stock
14/02/2024
CAMBRIDGE, Mass., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, today announced [...]
Celularity’s Tri-layer Decellularized, Dehydrated Human Amniotic Membrane Product Investigated as a Carrier of Induced Pluripotent Stem Cell Derived-Limbal Stem Cells in the Treatment of Severe Ocular Surface Disease
14/02/2024
-Highlights potential uses of Celularity biomaterials in regenerative medicine applications that combine stem cells and biomaterial scaffolds for use in constructing tissues and for cell delivery -Poster Presentation at [...]
WW International, Inc. Schedules Fourth Quarter and Full Year 2023 Earnings Conference Call
14/02/2024
NEW YORK, Feb. 14, 2024 (GLOBE NEWSWIRE) -- WW International, Inc. (NASDAQ: WW) (“WeightWatchers,” “WW,” or “the Company”) will release its results for the fourth quarter and full year 2023 after market close on [...]
Pennant Announces Fourth Quarter and Year-End 2023 Earnings Release and Call
14/02/2024
EAGLE, Idaho, Feb. 14, 2024 (GLOBE NEWSWIRE) -- The Pennant Group, Inc. (NASDAQ: PNTG), the parent company of operating subsidiaries that provide home health, hospice and senior living services, announced today that it [...]
Olansky Dermatology & Aesthetics welcomes Dr. Ajdin Kobic to acclaimed roster
14/02/2024
Board-certified dermatologist, Mohs micrographic, and reconstructive surgeon now providing care at Olansky Dermatology & Aesthetics ATLANTA, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Olansky Dermatology & Aesthetics – [...]
Genmab Files Annual Report with the U.S. Securities and Exchange Commission
14/02/2024
Media Release COPENHAGEN, Denmark; February 14, 2024 Genmab filed Form 20-F for the financial year 2023 with the U.S. SEC Genmab A/S (Nasdaq: GMAB) announced today that it has filed its Annual Report for the financial [...]
Starton Therapeutics Announces Opening of Second Clinical Site for STAR-LLD Phase 1b Trial in Multiple Myeloma and Provides Study Update
14/02/2024
Regional Medical Oncology Center is activated and open to screen patients Study enrollment is ahead of schedule with half of the patients enrolled and complete enrollment which was previously anticipated Q3/24 is now [...]
Processa Pharmaceuticals to Present at The Winter Wrap-Up MicroCap Rodeo Winter 2024 Virtual Conference
14/02/2024
HANOVER, MD, Feb. 14, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of [...]
Fresh Tracks Therapeutics Urges Stockholders to Vote at the Upcoming Special Meeting on February 15th
14/02/2024
Stockholders of record on January 11, 2024 who have not yet voted are encouraged to do so by 11:59 p.m. Eastern Time on February 14, 2024 BOULDER, Colo., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Fresh Tracks Therapeutics, Inc [...]
Gain Therapeutics Announces 2024 R&D Update on Parkinson’s Disease with KOL & Analyst Insight
14/02/2024
Event, moderated by Hartaj Singh and Eka Gigauri of Oppenheimer & Co., will be held on Thursday, February 22, 2024 at 11:00 am EST BETHESDA, Md., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc., (Nasdaq: [...]
EssilorLuxottica Q4/FY 2023 Results - 2023: another record year for EssilorLuxottica
14/02/2024
Q4/FY 2023 RESULTS 2023: another record year for EssilorLuxottica Group revenue at constant exchange rates 1 +7.1% in Q4 and FY, third consecutive year >7% Nice acceleration in North America in Q4, EMEA keeping the [...]
EssilorLuxottica résultats T4 et annuels 2023 - 2023: nouvelle année record pour EssilorLuxottica
14/02/2024
Résultats T4 et annuels 2023 2023 : nouvelle année record pour EssilorLuxottica Hausse de +7,1 % du chiffre d'affaires du Groupe au T4 et sur l’année à taux de change constants 1 ; troisième année consécutive supérieure [...]
EssilorLuxottica Board of Directors proposes nominees to the new Board
14/02/2024
EssilorLuxottica Board of Directors proposes nominees to the new Board Charenton-le-Pont, France (February 14, 2024 – 6:00pm) – During its meeting today, EssilorLuxottica Board of Directors decided to propose the re- [...]
EssilorLuxottica: Le Conseil d’administration d’EssilorLuxottica propose des candidats pour le nouveau conseil
14/02/2024
Le Conseil d’administration d’EssilorLuxottica propose des candidats pour le nouveau conseil Charenton-le-Pont, France (14 février 2024 – 18h00) – Réuni aujourd'hui, le Conseil d’administration d'EssilorLuxottica a [...]
Hyloris Enrolls First Patient in Phase 3 Clinical Trial for its Proprietary Mouth Rinse to Control Incidences of Bleeding Related to Dental Procedures
14/02/2024
Innovative oral care solution aims to benefit patients taking blood thinning medications, who have an increased risk of prolonged bleeding during and after dental procedures Approximately 280 patients in the EU and U.S [...]
Hyloris Recrute un Premier Patient dans le Cadre d'un Essai Clinique de Phase 3 portant sur son Rince-Bouche Breveté Destiné à Contrôler les Saignements lors des Interventions Dentaires
14/02/2024
Une solution innovante de soins bucco-dentaires destinée aux patients prenant des médicaments anticoagulants, qui présentent un risque accru de saignement prolongé au cours et à la suite d'interventions dentaires [...]
ACTG Announces Launch of Clinical Trial Evaluating Drug-Drug Interaction in Shortened Tuberculosis Regimen Among People Living with HIV
14/02/2024
LOS ANGELES, Feb. 14, 2024 (GLOBE NEWSWIRE) -- ACTG, a global clinical trials network focused on HIV and other infectious diseases, today announced the opening of study A5406 ( Pharmacokinetics and Safety of Double-dose [...]
Genmab Announces Initiation of Share Buy-Back Program
14/02/2024
Company Announcement Repurchase of up to 190,000 shares Honoring commitments under our Restricted Stock Unit program Completion expected on March 15, 2024 COPENHAGEN, Denmark; February 14, 2024 – Genmab A/S (Nasdaq: [...]

Pages